Evidence map›Paper›PMID 27418912›Full record

ArticleEXCLI journal2012

Prevalence of extended spectrum beta-lactamase production among uropathogens in south Mumbai and its antibiogram pattern.

K Aruna, T Mobashshera

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Extended-Spectrum Beta-Lactamase-ProducingFrontiers in public health · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

K ArunaDepartment of Microbiology, Wilson College, Mumbai- 400 007, India.
T MobashsheraDepartment of Microbiology, Wilson College, Mumbai- 400 007, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-lactams are the most widely used group of antimicrobials. However, increasing resistance to these valuable drugs in uropathogens, mediated principally by β-lactamases, has become a major concern. The present study was undertaken to determine the prevalence of Extended Spectrum β-Lactamase (ESBL) producers in clinical isolates of urine specimens, collected from various healthcare centres across south Mumbai. A total of 195 gram negative urine isolates were identified as Pseudomonas aeruginosa (13), Proteus mirabilis (21), Klebsiella pneumoniae (29), Escherichia coli (96), Enterobacter aerogenes (1), Enterobacter cloacae (1), Enterococcus fecalis (1), Morganella morganii (1), Citrobacter diversus (16), Citrobacter amalonaticus (5) and Proteus vulgaris (11). Antimicrobial Susceptibility Testing (AST) by Kirby-Bauer method showed 43.07 % (84/195) of the isolates were resistant to more than 70 % of the antibiotics used. Confirmatory screening using a combination of Double Disk Synergy Test (DDST), Phenotypic Confirmatory Disc Diffusion Test (PCDDT) and E-test revealed the overall prevalence of ESBL producers to be 34.71 % (68/195). The study showed 72.05 % of the ESBL producers to be resistant to fluoroquinolones, highlighting its extensive use in the region of south Mumbai. All ESBL producers were found to be sensitive to Imipenem whereas 82.36 % showed susceptibility to Amikacin making these 2 antibiotics the most effective choice of drug against ESBLs. In order to ensure rational treatment of highly resistant pathogens, the occurrence of ESBL and its primary studies may serve as a base for further research and findings.

Indexed as

beta-lactamdrug resistanceESBLuropathogens

Identifiers

PMID27418912
PMCPMC4942789
OpenAlexW2259217296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.